

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: August 8, 2023
PDL Changes Effective Date: October 1, 2023



The following changes will be made to the Preferred Drug List (PDL), effective October 1, 2023, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Movement Disorder Agents	Austedo XR (deutetrabenazine)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Antibiotics & Related, GI	Vowst (fecal microbiota)
Antimigraine Agents, Acute Treatment: CGRP Oral	Zavzpret (zavegepant)
Antipsychotics- Injectable, Atypicals	Abilify Asimtufii (aripiprazole)
Antipsychotics- Injectable, Atypicals	Uzedly (risperidone)
Factor Deficiency Products: Factor VIII	Altuviiiio (antihemophilic factor (recomb),
GI Ulcer Therapies: Proton Pump Inhibitors	Konvomep (omeprazole/sodium bicarb)
Growth Hormone	Sogroya (somapacitan-beco)
Hypoglycemics, Insulins and Related Agents	Rezvoglar (insulin glargine-aglr)
Lipotropics, Statins: Statins	Atorvaliq (atorvastatin)
Pulmonary Antihypertensives	Liqrev (sildenafil)